#TheStevieMackShow #Arch1Entertainment #BikeAttack
Tuesday, May 24, 2016
The Stevie Mack Show - Talent Showcase and Networking Mixer May 29 2016
#TheStevieMackShow #Arch1Entertainment #BikeAttack
Monday, May 16, 2016
CAN'T STOP THE FEELING! (From DreamWorks Animation's "Trolls") (Official...
I had a ball dancing in this this music video and Justin Timberlake is sooo cool, what an honor!
Thursday, May 05, 2016
Tuesday, May 03, 2016
Thursday, December 17, 2015
Saturday, December 12, 2015
Sunday, September 13, 2015
Jardiance Vs Januvia
Jardiance Vs Januvia
Will Jardiance dethrone
Januvia as a better treatment for Type 2 Diabetes? There are a lot of rumblings
in the medical community at this very minute that lean in that direction.
Yup! The medical world is on edge, awaiting results of an extended Jardiance study
to be released later this month at the European Association
for the Study of Diabetes annual meeting; that’s when we will all see if the benefits of the SGLT2 med (Jardiance)
will outweigh DPP-4 med (Januvia).
That is also when the investments in either stock will swing in
opposite directions. Get your dollars ready to make it rain …she’s bout to do a
sexy dance on the medical pole.
Stevie Mack
Actor/Comedian/Friend
About the blogger:
Stevie Mack is a blogger for many reasons, the main one being his love of entertainment.
Visit his website here: http://www,steviemack.com
_____________________________________________________________________________
Check out this article below for more:
While the markets gyrate rather wildly on concerns about emerging market growth -- or the lack thereof, more precisely -- we will take a moment to look forward, into 2016-2017, and predict that (if this preliminary study result holds up, upon peer review) Jardiance®may eat into Merck's more than $5 billion franchise, here. The Boehringer Ingelheim/Lilly drug is an SGLT2 inhibitor, and Merck's only current bet in this space is in a venture shared with Pfizer. That venture effort is not likely to reach market before 2018, in my estimation.
All of which is to say I think Merck would be quite vulnerable to product switching -- away from Januvia® -- should Jardiance turn out to provide a reduced cardio-vascular risk to most diabetes patients. [As we've reported before, repeatedly, Merck's presently-available study data shows only that there is no increased cardiovascular risk with Januvia.] Speaking broadly, and oversimplifying, here -- longer term cardio-vascular events are generally the proximate cause of disability/death for people with advanced diabetes. So it stands to reason that a drug able to mitigate that risk would be welcomed with open arms, by prescribing doctors. Here is BioPharma Dive's quite cogent take on it all:
All of which is to say I think Merck would be quite vulnerable to product switching -- away from Januvia® -- should Jardiance turn out to provide a reduced cardio-vascular risk to most diabetes patients. [As we've reported before, repeatedly, Merck's presently-available study data shows only that there is no increased cardiovascular risk with Januvia.] Speaking broadly, and oversimplifying, here -- longer term cardio-vascular events are generally the proximate cause of disability/death for people with advanced diabetes. So it stands to reason that a drug able to mitigate that risk would be welcomed with open arms, by prescribing doctors. Here is BioPharma Dive's quite cogent take on it all:
. . . .Merck's Januvia is often used as treatment for diabetes when metformin is not enough to control blood glucose. Diabetes is treated in a stepwise fashion, generally starting with metformin and adding on various classes of drugs over time. Given the new data published about Jardiance, Jardiance could become the go-to drug after metformin.
As mentioned in BioPharma Dive's coverage last week, the positive news about Jardiance, which is an SGLT-2 inhibitor could bode well for the entire class, including Johnson & Johnsons Invokana and Bristol-Myers Squibb's Farxiga. . . .
And so (from a larger, macro- perspective) -- in the longer run, the emerging markets will be a net positive for the solid counter cyclicals, like pharma and biotech. There may -- as ever -- be bumps along the way (as today is no doubt proving). . . Enjoy, one and all!
Source of article:
Friday, September 11, 2015
Edwonda White - Talkin Bout Lynwood
Here is the new music video #TalkinBoutLynwood by my sister in comedy Edwonda White - like it, share it and sing along! #Lynwood featuring Stevie Mack
Wednesday, August 12, 2015
Wednesday, July 29, 2015
Monday, July 20, 2015
Sunday, July 19, 2015
Tuesday, June 30, 2015
Monday, May 18, 2015
Wednesday, March 18, 2015
Tuesday, March 10, 2015
Thursday, February 26, 2015
#StevieMackRadio - Thursday Night Rant
#StevieMackRadio - Thursday Night Rant > broadcasting live on the air! Listen in now at http://tobtr.com/s/7370451. #BlogTalkRadio
Hot Tub Time Machine 2 - review by Stevie Mack
I got a chance to see hot tub
time machine today and it wasn't what I expected. It seemed like the best
part of the movie was in the end credits.
It wasn’t the laugh-out-loud riot
I expected. Sure, expectations are premeditated resentments, but my
expectations were based on the trailers and the fact that I was a big fan of
the original Hot Tub Time Machine.
Laughs throughout the movie
were very minimal and those laughs were mostly generated from shock humor. There were
a lot of uncomfortable chuckles here and there but that was about it.
I was hoping this movie would
raise the bar for another installment, Hot Tub Time Machine 3: Rise of the Pool
Cleaners … however this one missed
the mark and did not beat a path to that end.
The storyline focused on them
trying to right a wrong when it should have focused on them influencing various
important aspects of American and world history as they did in the end credits,
the stuff they teased us with in the trailers.
Here's some info about the movie from Rotten Tomatoes:
MOVIE INFO
Hot Tub Time Machine director Steve Pink returns to the helm for this sequel set 10 years in the future, and starring Rob Corddry, Adam Scott, Clark Duke, and Craig Robinson. ~ Jason Buchanan, Rovi
- R (for crude sexual content and language throughout, graphic nudity, drug use and some violence)
- Comedy
- Steve Pink
- Josh Heald
- Feb 20, 2015 Wide
- $6.0M
Paramount Pictures - Official Site
CAST
That's My Two Cents
About the blogger:
Stevie Mack is a blogger for many reasons, the
main one being his love of entertainment.
Tuesday, February 24, 2015
Subscribe to:
Posts (Atom)